ViaDerma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VDRM research report →
About the company
ViaDerma, Inc. , a specialty pharmaceutical enterprise based in the United States, focuses on both the development and commercialization of pharmaceutical products. It also licenses its proprietary technology to other companies within the pharmaceutical sector, addressing various therapeutic areas.
- CEO
- Christopher A Otiko
- IPO
- 2014
- Employees
- 75
- HQ
- Marina del Rey, CA, US
Price Chart
- Market Cap
- $370.11K
- P/E
- 86.23
- P/S
- 0.62
- P/B
- 2.87
- EV/EBITDA
- 8.46
- Div Yield
- 0.00%
- Gross Margin
- 99.97%
- Op Margin
- 30.85%
- Net Margin
- 0.68%
- ROE
- -0.48%
- ROIC
- 41.53%
- Revenue
- $600.50K · 11.07%
- Net Income
- $4.10K · -99.31%
- EPS
- $0.00 · -100.00%
- Op Income
- $185.27K
- FCF YoY
- 111.73%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.20
- Avg Volume
- 87.75K
Get TickerSpark's AI analysis on VDRM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our VDRM coverage
Recent articles, reports, and earnings notes.
No research on VDRM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VDRM report →Similar companies
Peers in the same neighborhood.